A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro
- 30 April 2008
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 31 (4) , 369-374
- https://doi.org/10.1016/j.ijantimicag.2007.11.015
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Measurement of Voriconazole Activity against Candida albicans , C. glabrata , and C. parapsilosis Isolates Using Time-Kill Methods Validated by High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strainsInternational Journal of Antimicrobial Agents, 2007
- Pharmacokinetic/Pharmacodynamic Profile of VoriconazoleClinical Pharmacokinetics, 2006
- Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialThe Lancet, 2005
- Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agentsExpert Review of Anti-infective Therapy, 2005
- Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic modelsInternational Journal of Antimicrobial Agents, 2005
- In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2003
- Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation RegimensAntimicrobial Agents and Chemotherapy, 2002